Clinical trials: Dendritic Cell
Acute Biphenotypic Leukemia, Acute Leukemia
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
This phase II trial tests how well removing CD45RA positive naive T cells works to prevent graft versus host disease in older patients undergoing standard of care allogeneic hematopoietic stem cell transplantation for the…
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT07819396
- Testing
- Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Melanoma
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells
This protocol was conducted as a single institution trial at Hoag Cancer Center, Hoag Hospital, Newport Beach, California. It was a single-arm phase II trial in which patients with metastatic melanoma received subcutaneous (s.c.)…
- Trial name
- DCVaccineMel (NCT00948480)
- Testing
- Autologous tumor cells plus dendritic cells, GM-CSF
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
This study is a prospective, non-randomized feasibility study. Freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT03860376
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Florida International University
Hepatocellular Carcinoma (HCC)
A Study of DC-CIK to Treat Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy of Dendritic and Cytokine-induced Killer Cells (DC-CIK) for hepatocellular carcinoma (HCC).
- Trial name
- NCT01821482
- Testing
- Dendritic and Cytokine-induced Killer Cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangxi Medical University
Glioblastoma Multiforme of Brain
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients
In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC)…
- Trial name
- ADDIT-GLIO (NCT02649582)
- Testing
- Dendritic cell vaccine plus temozolomide chemotherapy
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Antwerp
HBV, NASH - Nonalcoholic Steatohepatitis
Mechanism of DCs Dysfunction in Chronic HBV Infection
This research is to better understand the functional impairments of Dendritic cells (DCs) in chronic HBV infection. Aim is to determine if the virus is able to bind to the C-type lectin receptor (CLRs) of DCs to modulate their…
- Trial name
- HepatoDC (NCT03753308)
- Testing
- Blood Sampling, Liver biopsy
- Where
- France
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Prostate Cancer
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
- Trial name
- NCT00715078
- Testing
- sipuleucel-T
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Dendreon
Melanoma
Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients
Dendritic cells (DC) are the professional antigen presenting cells of the immune system. Multiple distinct DC lineage's exist and it is now well appreciated that the DC subset and the maturation stage of the DC determines the…
- Trial name
- NCT00847106
- Testing
- Daclizumab, Dendritic cells
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Colorectal Cancer, Metastatic Cancer
Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer
RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to kill their tumor cells.
- Trial name
- NCT00003433
- Testing
- carcinoembryonic antigen RNA-pulsed DC cancer vaccine
- Where
- United States
- Sponsor
- Duke Cancer Institute
Glioblastoma
Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma
This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated trial (IIT). The trial aims to evaluate the safety and tolerability of autologous dendritic cell injection sensitized with tumor…
- Trial name
- NCT07678138
- Testing
- Neoantigen DC Vaccine (YS247) for Glioblastoma
- Volunteers
- 9 people
- Sponsor
- Huanhu Hospital Affiliated to Tianjin Medical University
Adult Solid Tumor
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV as monotherapy and in combination with…
- Trial name
- NCT05357898
- Testing
- SQZ-eAPC-HPV, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- SQZ Biotechnologies
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill tumor cells.
- Trial name
- NCT00003792
- Testing
- MART-1 antigen, filgrastim, flu matrix peptide p58-66
- Where
- United States
- Sponsor
- Baylor Health Care System
Psoriatic Arthritis
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study
The purpose of this study is to determine whether DC-STAMP, a protein on the surface of osteoclast precursors (OCPs), can be used as a biologic marker in Psoriatic Arthritis (PsA).
- Trial name
- NCT01123265
- Testing
- Methotrexate, Anti-TNF
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Rochester
Triple Negative Breast Cancer, HER2-negative Breast Cancer
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast…
- Trial name
- DecipHER (NCT05504707)
- Testing
- HER2 - primed Dendritic cells, HER3 - primed Dendritic cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Leukemias, Burkitt's Lymphoma
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen.
- Conditions
- Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT02145039
- Testing
- Fludarabine, Cyclophosphamide, Total Body Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Renal Cancer Metastatic
A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma
Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and low dose anti-PD-1 antibody in patients with metastatic renal cell carcinoma treated with axitinib.
- Trial name
- NCT03736330
- Testing
- Combinations treatment
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
RATIONALE: Vaccines made from a person's dendritic cells and antigens may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00074230
- Testing
- Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- University Hospital Erlangen
Leukemia, Lymphoma
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
This is a phase I dose escalation study of DT2219ARL for the treatment of relapsed or refractory B-lineage leukemia and lymphoma. Patients will receive a single course of DT2219ARL as a 4 hour infusion on days 1, 3, 5, and 8.
- Trial name
- NCT00889408
- Testing
- DT2219ARL
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Colorectal Cancer
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment
The specific aims of this study are as follows: 1. Primary endpoint: to evaluate the clinical responses of vaccinated patients. 2.
- Trial name
- NCT00154713
- Testing
- CEA pulsed dendritic cells
- Where
- Taiwan
- Volunteers
- 37 people
- Sponsor
- National Taiwan University Hospital
Lymphoma, B-Cell, Lymphoma
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- NCT05940272
- Testing
- Hematolo-GIST Training, Participants Appointment
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center